Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 10:5:9642.
doi: 10.1038/srep09642.

The natural compound chebulagic acid inhibits vascular endothelial growth factor A mediated regulation of endothelial cell functions

Affiliations

The natural compound chebulagic acid inhibits vascular endothelial growth factor A mediated regulation of endothelial cell functions

Kai Lu et al. Sci Rep. .

Abstract

Vascular endothelial growth factor A (VEGFA) plays an important role in tumour angiogenesis and its angiogenic action is mainly mediated through its VEGF receptor 2 (VEGFR-2). Therefore drugs targeting VEGFA/VEGFR-2 are being presently used in the clinics for treatment of several types of solid malignant tumours. We here in report that low dose of chebulagic acid (CA), a hydrolysable tannin found in myrobalan fruits can inhibit VEGFA induced vascular permeability, endothelial cell proliferation, migration, tube formation and thereby, angiogenesis by suppressing VEGFR-2 phosphorylation. CA may thus be an effective and useful natural inhibitor of VEGFA mediated angiogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The plasma concentration of chebulagic acid (CA).
The plasma concentration-time profile of chebulagic acid in mice after oral ingestion of a single dose (100 mg/kg) of Triphala (n = 3). The error bars represent SEM.
Figure 2
Figure 2. The effects of chebulagic acid (CA) on the viability of endothelial cells.
The cytotoxic effects of 1, 2 and 5 μM of chebulagic acid (CA) on human umbilical vein cells (HUVEC) (*, p < 0.05). The error bars represent SEM. The data represent six separate experiments.
Figure 3
Figure 3. The effects of various concentrations of chebulagic acid (CA) on vascular endothelial growth factor A (VEGFA) mediated proliferation of endothelial cells.
VEGFA stimulated proliferation of human umbilical vein cells (HUVEC) when compared to untreated control (+, p < 0.05). However, this stimulatory effect was inhibited when these cells were also treated with 2 and 5 μM of CA (*, p < 0.05). The error bars represent SEM. The data represent six separate experiments.
Figure 4
Figure 4. The effects of chebulagic acid (CA) on vascular endothelial growth factor A (VEGFA) induced migration of human umbilical vein cells (HUVEC).
Phase-contrast photomicrographs demonstrated VEGFA induced complete wound closure or healing at 16 hr. On the contrary, this effect of VEGFA was abrogated when these cells were treated with 2 and 5 μM of CA. The wound healing was calculated as the distance covered by the cells in relation to the initial wound distance at 0 hr and is expressed as the percentage of initial distance at 0 hr. (*, P < 0.05). The error bars represent SEM. Scale bars in a, 200 um. The data represent six separate experiments.
Figure 5
Figure 5. The effects of chebulagic acid (CA) on vascular endothelial growth factor A (VEGFA) mediated tube formation in endothelial cells.
VEGFA stimulated tube formation in human umbilical vein cells (HUVEC) when compared to untreated control (+, p < 0.05). On the contrary, treatment with 2 and 5 μM of CA inhibited VEGFA induced endothelial cell tube formation (*, p < 0.05). Scale bars in (a), (b), (c), (d) and (e), 200 um. The data represent six separate experiments.
Figure 6
Figure 6. The effects of chebulagic acid (CA) on vascular endothelial growth factor A (VEGFA) induced permeability in endothelial cells.
In comparison to untreated control, VEGFA induced significant permeability in human umbilical vein cells (HUVEC) (+, p < 0.05). On the contrary, treatment with 2 or 5 μM of CA significantly inhibited VEGFA stimulated permeability in HUVEC (*, p < 0.05). The data represent six separate experiments.
Figure 7
Figure 7. The effects of chebulagic acid (CA) on vascular endothelial growth factor A (VEGFA) induced phosphorylation of VEGF receptor 2 (VEGFR-2).
Western blot analysis shows that in comparison to untreated control, VEGFA induced significant VEGFR-2 phosphorylation (+, p < 0.05). However, there was also a significant inhibition of VEGFA induced phosphorylation of VEGFR2 after treatment with 2 or 5 μM of CA (*, p < 0.05). The blot was re-probed with an antibody to β actin for comparison of equal protein load. Cropped gel images have been used in this figure and the gels were run under the same experimental conditions. The data represent six separate experiments. Full-length blots are presented in Supplementary Figure S1.
Figure 8
Figure 8. The effects of chebulagic acid (CA) on vascular endothelial growth factorA (VEGFA) induced new blood formation or angiogenesis in the CAM assay.
(a, f) Phosphate buffered saline (PBS) used as control did not induce blood vessel formation. (b, f) On the contrary, VEGFA stimulated new blood vessel formation. (c, f) 1 μM of CA did not inhibit VEGFA induced angiogenesis. (d, e, f) 2 or 5 μM of CA inhibited VEGFA induced new blood vessel formation. The photograph represents six separate experiments.

Similar articles

Cited by

References

    1. Dvorak H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368–4380 (2002). - PubMed
    1. Ferrara N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29, 789–791 (2009). - PubMed
    1. Sloan B. & Scheinfeld N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs. 9, 1324–1335 (2008). - PubMed
    1. Sullivan L. A. & Brekken R. A. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs. 2, 165–175 (2010). - PMC - PubMed
    1. Niraula S., Amir E., Vera-Badillo F., Seruga B., Ocana A. & Tannock I. F. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J. Clin. Oncol. 32, 3634–3642 (2014). - PubMed

Publication types

MeSH terms